



Minutes

BRI Institutional Biosafety Committee Institutional Biosafety Committee 6/9/2026 1:00 pm Zoom

1 Statements of Confidentiality and Conflicts of Interest

Quorum and Meeting Access: The Chair called the meeting to order at 1:01 pm and noted that the meeting was open to the public. Quorum existed at the start of the meeting with 8 voting members present. A quorum was maintained for the entire meeting.

Confidentiality: The Chair reminded the committee that while redacted meeting minutes will be made public, the information discussed should be considered confidential to protect the identity of individuals and the competitiveness of proprietary or technical information.

Conflict of Interest: The Chair asked the committee if any members needed to declare a conflict of interest with respect to any matter on the agenda. The Chair notified committee members that if they had a conflict of interest, they must leave the room during the final discussion and voting on that IBC submission.

2 Attendees

Committee Members Present

Lewis Bowen (Campus Operations)	Biological Safety Officer
Benjamin Gantner (Medicine)	Chair
Kunal Gupta (Neurosurgery)	R/SNA Technology Expert
Anna Huppler (Pediatrics)	R/SNA Technology Expert
Eric Jensen (Research Office)	Animal Containment Expert
Angela Mathison (Surgery)	R/SNA Technology Expert
Qizhen Shi (Pediatrics)	R/SNA Technology Expert
Matthew Surdel (Medicine)	R/SNA Technology Expert

Committee Members Absent

Kenneth Allen (Research Office)	Alternate Animal Containment Expert, Non-Voting
Lezi E (Cell Biology Neurobiology and Anatomy)	R/SNA Technology Expert
Tyce Kearl (Medicine)	R/SNA Technology Expert
	HGT Expert

Nikki Lytle (Surgery)
Sandy Montes-Gruber (Non-MCW)
Laura Stephens (Non-MCW)

R/SNA Technology Expert
Non-Affiliated Member
Non-Affiliated Member

3 Meeting Minutes Reviewed at this Meeting

05/12/2026 (Zoom)

Motion: Minutes Approved
Yes Votes: 8
No Votes: 0
Abstained: 0
Recused: 0
Total Votes: 8

4 New Business

1. Administrative Report

The Chair asked the Committee Members to review the Administrative Report and then invited discussion. No concerns were raised.

2. Exempt Rodent Report

The Exempt Rodent Report was provided to the Committee members.

5 Application Reviews

IBC20260018 CD36 in Cardiovascular disease

Principal Investigator: Yiliang Chen
Motion: Decision Pending Changes
Yes Votes: 8
No Votes: 0
Abstained: 0
Recused: 0
Total Votes: 8

NIH Guidelines: Section III-D-1, Section III-D-2, Section III-D-4, Section III-E, Section III-F-1, Section III-F-8 (C-I), Section III-F-8 (C-II)

Biosafety Level(s): BSL1, BSL2

Deliberations: The Chair introduced this new Institutional Biosafety Committee (IBC) application, and the Secondary Reviewer went on to describe the study. The Principal Investigator (PI) wishes to examine how CD36 activation in platelets, endothelial cells, and macrophages contributes to atherosclerosis. Recombinant DNA (rDNA) and lentiviral vectors will be used to manipulate the expression of signaling molecules, including CD36, Na⁺/K⁺-ATPase, PGC1alpha, and TLR4, in human and mouse cells in vitro and in mice in vivo. The Committee confirmed that all personnel listed in the application completed safety training appropriate for work with the materials described. The Primary and Secondary Reviewers requested a few changes, including that the PI clarify how the cells in the application will be used, specify the potential risks associated with working on human cells, and clarify whether human or mouse exosomes, or both, will be administered to animals. The Animal Containment Expert (ACE) requested that the PI clarify whether they will be administering biological materials to animals in animal biological safety level (ABSL)1 procedure room, and if so, the procedures that will be followed to bring the containment in the room to ABSL2 during administration and then to bring the room back to ABSL1 compliance. The Biological Safety Officer (BSO) requested that the PI clarify if human extracellular vesicles will be administered to animals and noted that the entries for recombinant animal materials that will be administered to animals will need to include NIH

5**Application Reviews**

Guideline Section III-D-4. After brief discussion, upon a motion duly made by the Primary Reviewer and seconded, the Committee voted to approve this application pending the requested changes.

6**Adjournment**

There being no further business, the meeting was adjourned at 1:25 pm. The next regularly scheduled meeting will be held on Tuesday, July 14, 2026 at 1:00 pm in Zoom.